CL2020001542A1 - Ligandos de psma para la formación de imágenes y endorradioterapia. - Google Patents
Ligandos de psma para la formación de imágenes y endorradioterapia.Info
- Publication number
- CL2020001542A1 CL2020001542A1 CL2020001542A CL2020001542A CL2020001542A1 CL 2020001542 A1 CL2020001542 A1 CL 2020001542A1 CL 2020001542 A CL2020001542 A CL 2020001542A CL 2020001542 A CL2020001542 A CL 2020001542A CL 2020001542 A1 CL2020001542 A1 CL 2020001542A1
- Authority
- CL
- Chile
- Prior art keywords
- endoradiation
- imaging
- psma
- psma ligands
- compounds
- Prior art date
Links
- 238000003384 imaging method Methods 0.000 title abstract 2
- 239000003446 ligand Substances 0.000 title 1
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 abstract 3
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000000163 radioactive labelling Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Optics & Photonics (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Nuclear Medicine (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente divulgación se refiere a la formación de imágenes y endorradioterapia de enfermedades que implican antígeno de membrana específico de próstata (PSMA). Se proporcionan compuestos que unen o inhiben PSMA y adicionalmente llevan al menos una fracción que es susceptible de radiomarcaje. También se porporcionan usos médicos de dichos compuestos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17206510 | 2017-12-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2020001542A1 true CL2020001542A1 (es) | 2020-10-02 |
Family
ID=60654872
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2020001542A CL2020001542A1 (es) | 2017-12-11 | 2020-06-10 | Ligandos de psma para la formación de imágenes y endorradioterapia. |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US11497819B2 (es) |
| EP (2) | EP4008359A1 (es) |
| JP (2) | JP7317375B2 (es) |
| KR (1) | KR20200097690A (es) |
| CN (2) | CN116617421A (es) |
| AU (1) | AU2018382479A1 (es) |
| BR (1) | BR112020011727A2 (es) |
| CA (1) | CA3078104A1 (es) |
| CL (1) | CL2020001542A1 (es) |
| CR (1) | CR20200241A (es) |
| CU (1) | CU24677B1 (es) |
| DK (1) | DK3723815T3 (es) |
| EC (1) | ECSP20029142A (es) |
| ES (1) | ES2914832T3 (es) |
| HR (1) | HRP20220764T1 (es) |
| HU (1) | HUE059083T2 (es) |
| IL (2) | IL274072B1 (es) |
| JO (1) | JOP20200135A1 (es) |
| LT (1) | LT3723815T (es) |
| MX (2) | MX2020005430A (es) |
| PE (1) | PE20210456A1 (es) |
| PL (1) | PL3723815T3 (es) |
| PT (1) | PT3723815T (es) |
| RS (1) | RS63279B1 (es) |
| SG (1) | SG11202002965WA (es) |
| SI (1) | SI3723815T1 (es) |
| TN (1) | TN2020000072A1 (es) |
| UA (1) | UA126413C2 (es) |
| WO (1) | WO2019115547A1 (es) |
| ZA (1) | ZA202003472B (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2914832T3 (es) | 2017-12-11 | 2022-06-16 | Univ Muenchen Tech | Ligandos de PSMA para la formación de imágenes y endorradioterapia |
| CA3144094A1 (en) | 2019-06-21 | 2020-12-24 | Provincial Health Services Authority | Radiolabeled compounds targeting the prostate-specific membrane antigen |
| CN112321673B (zh) * | 2020-11-04 | 2022-09-20 | 北京市肿瘤防治研究所 | 一种前列腺特异性膜抗原靶向抑制剂及应用和探针 |
| CN113354707A (zh) * | 2021-06-07 | 2021-09-07 | 苏州思萃同位素技术研究所有限公司 | 一种针对前列腺癌的三功能诊疗一体化药物前体的合成方法及其产品 |
| WO2023173074A2 (en) * | 2022-03-10 | 2023-09-14 | The Research Foundation For The State University Of New York | Immunostimulant-cytotoxic conjugate composition and methods for cancer treatment |
| CN115010629B (zh) * | 2022-06-07 | 2024-02-23 | 西南医科大学附属医院 | 前列腺特异性膜抗原抑制剂、其核素标记物及制法和应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1888581A2 (en) | 2005-05-16 | 2008-02-20 | Gilead Sciences, Inc. | Hiv-integrase inhibitor compounds |
| HUE059436T2 (hu) * | 2008-08-01 | 2022-11-28 | Univ Johns Hopkins | PSMA-kötõ szerek és alkalmazásaik |
| WO2010135431A2 (en) * | 2009-05-19 | 2010-11-25 | The Regents Of The University Of California | Compositions, devices, and methods related to prostate-specific membrane antigen |
| EP4374924A2 (en) * | 2013-10-18 | 2024-05-29 | Novartis AG | Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
| US10683272B2 (en) | 2014-05-06 | 2020-06-16 | The Johns Hopkins University | Metal/radiometal-labeled PSMA inhibitors for PSMA-targeted imaging and radiotherapy |
| US10688200B2 (en) | 2015-12-31 | 2020-06-23 | Five Eleven Pharma Inc. | Urea-based prostate specific membrane antigen (PSMA) inhibitors for imaging and therapy |
| WO2017165473A1 (en) * | 2016-03-22 | 2017-09-28 | The Johns Hopkins University | Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer |
| ES2914832T3 (es) | 2017-12-11 | 2022-06-16 | Univ Muenchen Tech | Ligandos de PSMA para la formación de imágenes y endorradioterapia |
| EP3724176B1 (en) | 2017-12-11 | 2022-01-26 | Helsinn Healthcare SA | Fumarate salt of (r)-3-(1-(2,3-dichloro-4-(pyrazin-2-yl)phenyl)-2,2,2-trifluoroethyl)-1-methyl-1-(1-methylpiperidin-4-yl) urea, methods of preparation, and uses thereof |
| TW201930265A (zh) | 2017-12-11 | 2019-08-01 | 西班牙商阿爾米雷爾有限公司 | 作為acc抑制劑的吡咯衍生物 |
-
2018
- 2018-12-11 ES ES18812215T patent/ES2914832T3/es active Active
- 2018-12-11 US US16/765,729 patent/US11497819B2/en active Active
- 2018-12-11 CN CN202310801735.3A patent/CN116617421A/zh active Pending
- 2018-12-11 TN TNP/2020/000072A patent/TN2020000072A1/en unknown
- 2018-12-11 MX MX2020005430A patent/MX2020005430A/es unknown
- 2018-12-11 SG SG11202002965WA patent/SG11202002965WA/en unknown
- 2018-12-11 CR CR20200241A patent/CR20200241A/es unknown
- 2018-12-11 CA CA3078104A patent/CA3078104A1/en active Pending
- 2018-12-11 KR KR1020207014036A patent/KR20200097690A/ko not_active Application Discontinuation
- 2018-12-11 UA UAA202003533A patent/UA126413C2/uk unknown
- 2018-12-11 HU HUE18812215A patent/HUE059083T2/hu unknown
- 2018-12-11 PL PL18812215.4T patent/PL3723815T3/pl unknown
- 2018-12-11 CN CN201880056196.2A patent/CN111182927B/zh active Active
- 2018-12-11 JO JOP/2020/0135A patent/JOP20200135A1/ar unknown
- 2018-12-11 CU CU2020000052A patent/CU24677B1/es unknown
- 2018-12-11 HR HRP20220764TT patent/HRP20220764T1/hr unknown
- 2018-12-11 EP EP21218180.4A patent/EP4008359A1/en active Pending
- 2018-12-11 SI SI201830691T patent/SI3723815T1/sl unknown
- 2018-12-11 DK DK18812215.4T patent/DK3723815T3/da active
- 2018-12-11 LT LTEPPCT/EP2018/084399T patent/LT3723815T/lt unknown
- 2018-12-11 RS RS20220527A patent/RS63279B1/sr unknown
- 2018-12-11 PE PE2020000552A patent/PE20210456A1/es unknown
- 2018-12-11 PT PT188122154T patent/PT3723815T/pt unknown
- 2018-12-11 WO PCT/EP2018/084399 patent/WO2019115547A1/en active Application Filing
- 2018-12-11 AU AU2018382479A patent/AU2018382479A1/en active Pending
- 2018-12-11 BR BR112020011727-7A patent/BR112020011727A2/pt unknown
- 2018-12-11 EP EP18812215.4A patent/EP3723815B1/en active Active
- 2018-12-11 JP JP2020526146A patent/JP7317375B2/ja active Active
-
2020
- 2020-04-20 IL IL274072A patent/IL274072B1/en unknown
- 2020-06-03 EC ECSENADI202029142A patent/ECSP20029142A/es unknown
- 2020-06-10 CL CL2020001542A patent/CL2020001542A1/es unknown
- 2020-06-10 ZA ZA2020/03472A patent/ZA202003472B/en unknown
- 2020-07-13 MX MX2023005053A patent/MX2023005053A/es unknown
-
2022
- 2022-07-15 US US17/866,034 patent/US20230122957A1/en active Pending
-
2023
- 2023-07-11 JP JP2023113523A patent/JP2023139063A/ja active Pending
-
2024
- 2024-05-26 IL IL313103A patent/IL313103A/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2020001542A1 (es) | Ligandos de psma para la formación de imágenes y endorradioterapia. | |
| CL2017003021A1 (es) | Agentes de unión a inmunorreceptor de células t con dominios ig y motivo de inhibición basado en tirosina de inmunorreceptor (tigit) y usos de los mismos. | |
| DOP2018000280A (es) | Compuestos moduladores de fxr (nr1h4) | |
| MX2021008977A (es) | Inhibidores marcados de antigeno prostatico especifico de membrama (psma), su uso como agentes formadores de imagenes y agentes farmaceuticos para el tratamiento de cancer de prostata. | |
| SV2016005180A (es) | Amino-heteroaril-benzamidas como inhibidores de cinasa | |
| CU20170172A7 (es) | 4,6-diaminoquinolin-3-carbonitrilos sustituidos útiles como agentes analgésicos, antipiréticos o antiinflamatorios y antineoplásicos | |
| BR112016000903A2 (pt) | anticorpos | |
| UY36757A (es) | Anticuerpos monoclonales murinos contra cd40 con actividad agonista mejorada | |
| UY33850A (es) | Anticuerpos anti ? cd38 | |
| DOP2021000049A (es) | Anticuerpos anti-hla-g, composiciones que comprenden anticuerpos anti-hla-g y métodos de uso de anticuerpos anti-hla-g | |
| BR112016025470A2 (pt) | ?hdl terapêutico? | |
| CY1123790T1 (el) | Σημασμενοι me 18f αναστολεις του ειδικου προστατικου αντιγονου της μεμβρανης (psma) και χρηση τους ως απεικονιστικα μεσα για τον καρκινο του προστατη | |
| MX2020009130A (es) | Anticuerpos terapéuticos anti-spla2-gib y los usos de los mismos. | |
| CL2017000212A1 (es) | Anticuerpos anti proteína similar a angiopoyetina 4 y métodos de uso | |
| AR101671A1 (es) | Anticuerpos anti proteína similar a angiopoyetina-4 (angptl4) y métodos de uso | |
| BR112017002675A2 (pt) | métodos para aperfeiçoar desempenho miocárdico em pacientes de fontan com o uso de composições de udenafila | |
| DOP2019000021A (es) | Derivado de triazolopirazinona útil como un inhibidor de pde1 humana | |
| CU20140047A7 (es) | Anticuerpo humanizados que reconocen la alfa- sinucleina | |
| CR20160175A (es) | Amino-heteroaril-benzamidas como inhibidores de cinasa |